9 unknown. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Unknown 9 |
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis Ruxolitinib - Myelofibrosis | Phase 4 | Unknown | Qilu Hospital of Shandong University | 87 | 2022-06-10 | 2022-07-07 |
| A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg) - CML, Chronic Phase | Phase 4 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 200 | 2021-11-23 | 2022-04-29 |
| Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure Flumatinib - Flumatinib, Chronic Myeloid Leukemia, Chronic Phase | Phase 4 | Unknown | Shenzhen Second People's Hospital | 200 | 2021-01-01 | 2022-03-16 |
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP Dasatinib - Dasatinib, BCR-ABL | Phase 4 | Unknown | Shenzhen Second People's Hospital | 65 | 2019-12-01 | 2022-07-27 |
| Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Imatinib, Nilotinib - Chronyc Myeloid Leukemia | Phase 4 | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 450 | 2016-11-11 | 2022-01-20 |
| Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Dasatinib 50 MG - Chronic Myelogenous Leukemia | Phase 4 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 12 | 2016-04-01 | 2017-07-13 |
| Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Nilotinib - Leukemia, Chronic Myeloid | Phase 4 | Unknown | Samsung Medical Center | 40 | 2015-04-01 | 2015-03-17 |
| Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Imatinib - Chronic Myeloid Leukemia | Phase 4 | Unknown | Cttq | 90 | 2015-02-01 | 2014-12-15 |
| Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Growth Hormone - Chronic Myelogenous Leukemia, Short Stature | Phase 4 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 20 | 2013-01-01 | 2013-07-17 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia, Myeloid, Chronic-Phase (2) · Dwarfism (1) · Primary Myelofibrosis (1)
Bone Marrow Diseases (9) · Hematologic Diseases (9) · Hemic and Lymphatic Diseases (9) · Chronic Disease (8) · Disease Attributes (8) · Leukemia (8) · Leukemia, Myeloid (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Bone Diseases (1) · Bone Diseases, Developmental (1)
Dasatinib (2) · Imatinib Mesylate (2) · nilotinib (2) · Growth Hormone (1) · flumatinib (1) · ruxolitinib (1)
Shenzhen Second People's Hospital (2) · Cttq (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Qilu Hospital of Shandong University (1) · Samsung Medical Center (1)
China (4) · India (1) · Italy (1) · Mexico (1) · Netherlands (1)
Fabrizio Pane (1) · Jun Ma (1) · Xin Du, Phd (1)